FATE
Fate Therapeutics, Inc.
Set alert
2.08 USD -0.09 -4.15%
2.01 Day range 2.16
0.96 52-week range 3.11
- YTD
- +112.24%
- 1 year
- +61.24%
- Open
- 2.13
- Prev close
- 2.17
- Mkt cap
- 249.23M
- Vol
- 1.06M
- Avg vol
- 1.58M
- EPS
- -1.05
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.01
- High
- 2.16
- Forward P/E
- -0.99
- Beta
- 1.88
- Short ratio
- 3.10
- Inst. own
- 102.25%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.53
- 200-d avg
- 3.93
- 1y target
- 6.31
Key statistics
- Market cap
- 189.06M
- Enterprise value
- -6.60M
- Trailing P/E
- 0.00
- Forward P/E
- -0.99
- PEG ratio
- 0.00
- Price / sales
- 14.06
- Price / book
- 0.52
- EPS (TTM)
- -1.64
- Beta
- 1.88
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 13.45M
- Revenue growth
- 58.10%
- Free cash flow
- -58.50M
- Total cash
- 296.92M
- Total debt
- 98.98M
- Return on equity
- -46.59%
- Shares outstanding
- 113.89M
- Short % of float
- 11.43%
- 50-day average
- 2.53
- 200-day average
- 3.93
Analyst view
Consensus: buy
Buy
Price target (mean) 6.31 +203.3% upside
Now 2.08
- Target (low)
- 3.00
- Target (mean)
- 6.31
- Target (high)
- 10.00
Ratings (0m) 18 6 buy · 12 hold · 0 sell
- Strong buy2
- Buy4
- Hold12
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.43055.
Financials — quick view
FATE Revenue — quarterly 2.08M
FATE Net income — quarterly -30.16M
FATE EPS — quarterly -0.25
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.42 | -0.40 | +0.02 | +4.76% |
| Aug 13, 2024 | Jun 1, 2024 | -0.47 | -0.33 | +0.14 | +29.79% |
| May 9, 2024 | Mar 1, 2024 | -0.47 | -0.47 | 0.00 | 0.00% |
| Feb 26, 2024 | Dec 1, 2023 | -0.57 | -0.45 | +0.12 | +21.05% |
| Nov 8, 2023 | Sep 1, 2023 | -0.59 | -0.46 | +0.13 | +22.03% |
| Aug 8, 2023 | Jun 1, 2023 | -0.58 | -0.54 | +0.04 | +6.90% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 19, 2024 | Needham | reit | — | Hold |
| Nov 13, 2024 | Needham | reit | — | Hold |
| Aug 22, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Aug 14, 2024 | Needham | reit | — | Hold |
| Jun 17, 2024 | Piper Sandler | up | Neutral | Overweight |
| May 16, 2024 | HC Wainwright & Co. | main | Neutral | Neutral |
About Fate Therapeutics, Inc.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- fatetherapeutics.com
News
- Wedbush Reiterates Outperform on Fate Therapeutics, Maintains $7 Price Target
- Fate Therapeutics Presents Updated Phase 1 Clinical Data For FT819, Off-The-Shelf, Available On-Demand, Anti-CD19 CAR T-Cell Product Candidate, In Patients With SLE With Lupus Nephritis At ASN Kidney Week 2026
- Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026
- Fate Therapeutics Receives $15M CIRM Grant To Advance Phase 2 FT819 Trial In Lupus Nephritis
- Fate Therapeutics Says Four Abstracts From Off-The-Shelf CAR T-Cell Programs Selected For Presentation At ACR Convergence 2026
- Fate Therapeutics To Present Clinical Data From Off-The-Shelf Anti-CD19 CAR T-Cell Product Candidate FT819, And Pre-Clinical Data From Anti-CD19 And CD38 CAR T-Cell Product Candidate FT839 At CCR – West Meeting
- Piper Sandler Reiterates Overweight on Fate Therapeutics, Raises Price Target to $8
- Wells Fargo Maintains Equal-Weight on Fate Therapeutics, Raises Price Target to $3.5
- Wedbush Reiterates Outperform on Fate Therapeutics, Maintains $7 Price Target
- Fate Therapeutics Highlights Initiation Of And Treatment Of First Patient In RECLAIM-LN, Phase 2 Potentially Registrational Clinical Trial Of FT819 In Patients With Refractory Moderate-To-Severe SLE With Lupus Nephritis
Your note
Sign in to keep a note on FATE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHU YU-WAYE | Officer | Sale | Apr 17, 2023 | 140,676 |
| DULAC EDWARD J III | Chief Financial Officer | Sale | Mar 3, 2024 | 101,479 |
| MENDLEIN JOHN D | Director | Conversion of Exercise of derivative security | Jan 18, 2023 | 311,231 |
| PLAVSIC MARK | Chief Technology Officer | Sale | Jan 9, 2023 | 123,705 |
| POWL BRIAN T | Officer | Sale | Jul 4, 2023 | 41,146 |
| REDMILE GROUP, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Dec 11, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Redmile Group, LLC | 11.56% | 13,169,057 | 21.86M | Sep 29, 2024 |
| Blackrock Inc. | 9.20% | 10,473,250 | 17.39M | Sep 29, 2024 |
| Vanguard Group Inc | 9.13% | 10,404,123 | 17.27M | Sep 29, 2024 |
| Deep Track Capital, Lp | 4.89% | 5,572,607 | 9.25M | Sep 29, 2024 |
| State Street Corporation | 4.61% | 5,252,974 | 8.72M | Sep 29, 2024 |
| Boxer Capital, LLC | 4.36% | 4,960,910 | 8.24M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.68% | 3,049,285 | 5.06M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.27% | 2,582,631 | 4.29M | Oct 30, 2024 |
| Vanguard Strategic Equity Fund | 2.23% | 2,540,354 | 4.22M | Sep 29, 2024 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 2.16% | 2,464,707 | 4.09M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.24% | 1,409,518 | 2.34M | Sep 29, 2024 |
| Vanguard Explorer Fund, Inc. | 1.11% | 1,268,133 | 2.11M | Jul 30, 2024 |